222 related articles for article (PubMed ID: 24349500)
21. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
22. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
Moghaddam A; Melum E; Reinton N; Ring-Larsen H; Verbaan H; Bjøro K; Dalgard O
Hepatology; 2011 Mar; 53(3):746-54. PubMed ID: 21374656
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.
Kawaoka T; Takahashi S; Takaki S; Hiramatsu A; Waki K; Hiraga N; Miki D; Tsuge M; Imamura M; Kawakami Y; Aikata H; Ochi H; Onoe T; Tashiro H; Ohdan H; Chayama K
J Gastroenterol Hepatol; 2012 Sep; 27(9):1467-72. PubMed ID: 22432893
[TBL] [Abstract][Full Text] [Related]
24. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
Rallón NI; Soriano V; Naggie S; Restrepo C; Goldstein D; Vispo E; McHutchison J; Benito JM
AIDS; 2011 May; 25(8):1025-33. PubMed ID: 21505315
[TBL] [Abstract][Full Text] [Related]
25. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
[TBL] [Abstract][Full Text] [Related]
26. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
[TBL] [Abstract][Full Text] [Related]
27. Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis.
Bota S; Sporea I; Şirli R; Neghină AM; Popescu A; Străin M
Clin Drug Investig; 2013 May; 33(5):325-31. PubMed ID: 23532802
[TBL] [Abstract][Full Text] [Related]
28. Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.
Chen MY; Liu CH; Chen TC; Su TH; Chen PJ; Chen DS; Kao JH; Liu CJ
J Gastroenterol Hepatol; 2014 Jan; 29(1):102-9. PubMed ID: 23829453
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.
Huang CF; Huang JF; Yang JF; Hsieh MY; Lin ZY; Chen SC; Wang LY; Juo SH; Chen KC; Chuang WL; Kuo HT; Dai CY; Yu ML
J Hepatol; 2012 Jan; 56(1):34-40. PubMed ID: 21703176
[TBL] [Abstract][Full Text] [Related]
30. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
[TBL] [Abstract][Full Text] [Related]
31. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.
Ogawa E; Furusyo N; Murata M; Ikezaki H; Ihara T; Hayashi T; Toyoda K; Taniai H; Okada K; Kainuma M; Hayashi J
J Hepatol; 2012 Sep; 57(3):534-40. PubMed ID: 22613000
[TBL] [Abstract][Full Text] [Related]
32. Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection.
Huang CI; Huang CF; Huang JF; Dai CY; Yeh ML; Hsieh MY; Lin ZY; Chen SC; Wang LY; Yu ML; Chuang WL
J Gastroenterol Hepatol; 2014 May; 29(5):1012-8. PubMed ID: 24325201
[TBL] [Abstract][Full Text] [Related]
33. Diversity of killer cell immunoglobulin-like receptor (KIR) genotypes and KIR2DL2/3 variants in HCV treatment outcome.
Vidal-Castiñeira JR; López-Vázquez A; Martínez-Borra J; Martínez-Camblor P; Prieto J; López-Rodríguez R; Sanz-Cameno P; de la Vega J; Rodrigo L; Pérez-López R; Pérez-Álvarez R; López-Larrea C
PLoS One; 2014; 9(6):e99426. PubMed ID: 24927414
[TBL] [Abstract][Full Text] [Related]
34. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4.
Antaki N; Bibert S; Kebbewar K; Asaad F; Baroudi O; Alideeb S; Hadad M; Abboud D; Sabah H; Bochud PY; Negro F
J Viral Hepat; 2013 Jan; 20(1):59-64. PubMed ID: 23231085
[TBL] [Abstract][Full Text] [Related]
35. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
[TBL] [Abstract][Full Text] [Related]
36. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
[TBL] [Abstract][Full Text] [Related]
37. Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin.
Lyoo K; Song MJ; Hur W; Choi JE; Hong SW; Kim CW; Bae SH; Choi JY; Choi SW; Shin EC; Yoon SK
J Clin Virol; 2011 Dec; 52(4):363-6. PubMed ID: 21907615
[TBL] [Abstract][Full Text] [Related]
38. Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C.
Masaki N; Sugiyama M; Shimada N; Tanaka Y; Nakamuta M; Izumi N; Watanabe S; Tsubota A; Komatsu M; Masaki T; Enomoto N; Yoneda M; Murata K; Ito K; Koike K; Mizokami M
J Gastroenterol Hepatol; 2014 Dec; 29(12):1996-2005. PubMed ID: 24910341
[TBL] [Abstract][Full Text] [Related]
39. IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C.
Sedighimehr P; Irani S; Sakhaee F; Vaziri F; Aghasadeghi M; Sadat SM; Jamnani FR; Fateh A; Siadat SD
Arch Virol; 2017 Jan; 162(1):181-189. PubMed ID: 27714501
[TBL] [Abstract][Full Text] [Related]
40. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin.
McCarthy JJ; Li JH; Thompson A; Suchindran S; Lao XQ; Patel K; Tillmann HL; Muir AJ; McHutchison JG
Gastroenterology; 2010 Jun; 138(7):2307-14. PubMed ID: 20176026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
